TransCode Therapeutics Inc [NASDAQ: RNAZ] gained 38.71% or 0.15 points to close at $0.56 with a heavy trading volume of 129518310 shares.
The daily chart for RNAZ points out that the company has recorded -97.14% loss over the past six months.
If we look at the average trading volume of 7.15M shares, RNAZ reached to a volume of 129518310 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about TransCode Therapeutics Inc [RNAZ]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RNAZ shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RNAZ stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Trading performance analysis for RNAZ stock
TransCode Therapeutics Inc [RNAZ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 41.00. With this latest performance, RNAZ shares gained by 4.27% in over the last four-week period, additionally sinking by -97.14% over the last 6 months – not to mention a drop of -97.09% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RNAZ stock in for the last two-week period is set at 42.12, with the RSI for the last a single of trading hit 60.58, and the three-weeks RSI is set at 37.72 for TransCode Therapeutics Inc [RNAZ]. The present Moving Average for the last 50 days of trading for this stock 1.3395, while it was recorded at 0.4409 for the last single week of trading, and 8.8479 for the last 200 days.
TransCode Therapeutics Inc [RNAZ]: A deeper dive into fundamental analysis
TransCode Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.56 and a Current Ratio set at 2.56.
An analysis of Institutional ownership at TransCode Therapeutics Inc [RNAZ]
There are presently around $0.71%, or 0.71%% of RNAZ stock, in the hands of institutional investors.
